Pacific Biosciences of California, Inc. (PACB) Stock Rises on Q1 2026 Earnings

Pacific Biosciences of California, Inc. (PACB) reported first-quarter 2026 results.

Revenue: $37.2 million (up 0.07% year-over-year)

Gross profit: $13.0 million (up 337.93% year-over-year)

Operating profit: -$8.4 million (down 98.05% year-over-year)

Net income attributable to common shareholders: -$8.3 million (down 98.06% year-over-year)

Diluted earnings per share: -$0.03 (down 97.92% year-over-year)

Cash and cash equivalents: $276.0 million (up 371.67% year-over-year)

Cash from operating activities: -$19.1 million (down 56.72% year-over-year)

Purchases of property, plant and equipment: -$0.9 million (down 38.01% year-over-year)

Cost of sales: $24.2 million (down 29.33% year-over-year)

Total liabilities: $780.0 million (up 1.41% year-over-year)

Revenue versus estimate: reported $37.2 million versus estimate $40.8 million

EPS versus estimate: reported -$0.03 versus estimate -$0.14

Stock price change since market close: 2.65%

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Pacific Biosciences Of California, Inc. Insider Trading Activity

Pacific Biosciences Of California, Inc. insiders have traded $PACB stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $PACB stock by insiders over the last 6 months:

CHRISTIAN O HENRY (See Remarks) has made 0 purchases and 3 sales selling 485,164 shares for an estimated $771,309.
OENE MARK VAN (See Remarks) has made 0 purchases and 3 sales selling 191,401 shares for an estimated $304,165.
JAMES R II GIBSON (See Remarks) sold 88,185 shares for an estimated $120,813
MICHELE FARMER (See Remarks) has made 0 purchases and 3 sales selling 53,146 shares for an estimated $84,365.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

Pacific Biosciences Of California, Inc. Hedge Fund Activity

We have seen 111 institutional investors add shares of Pacific Biosciences Of California, Inc. stock to their portfolio, and 87 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

EDMOND DE ROTHSCHILD HOLDING S.A. removed 10,675,200 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $19,962,624
ARK INVESTMENT MANAGEMENT LLC added 6,340,125 shares (+20.5%) to their portfolio in Q4 2025, for an estimated $11,856,033
MADRONE ADVISORS, LLC removed 4,976,089 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,305,286
D. E. SHAW & CO., INC. added 4,438,273 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,299,570
RENAISSANCE TECHNOLOGIES LLC added 3,850,600 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,200,622
CASDIN CAPITAL, LLC added 3,500,000 shares (+483.6%) to their portfolio in Q4 2025, for an estimated $6,545,000
POINT72 ASSET MANAGEMENT, L.P. added 2,957,400 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,530,338

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

Pacific Biosciences Of California, Inc. Government Contracts

We have seen $2,315,678 of award payments to $PACB over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

VEGA BENCHTOP LONG READ SEQUENCER FROM PACIFIC BIOSCIENCES A LONG READ GENOMIC SEQUENCER THAT PROVIDES HIG...: $343,000
PACBIO REAGENT KITS. ALL REAGENTS FOR SEQUENCING 24 REVIO SMRT CELLS QUANTITY 8, AND ASSOCIATED LIBRARY PRE...: $232,853
REVIO SMRT CELLS AND SEQUENCING REAGENTS - NEW AWARD: $198,082
REVIO SPRQ REAGENT KIT, 24-PACK, PACIFIC BIOSCIENCES OF CALIFORNIA (NON-IT): $194,860
PACBIO SEQUENCING SUPPLIES: $97,560

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Pacific Biosciences Of California, Inc. Analyst Ratings

Wall Street analysts have issued reports on $PACB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Stephens & Co. issued a "Overweight" rating on 11/10/2025

To track analyst ratings and price targets for Pacific Biosciences Of California, Inc., check out Quiver Quantitative's $PACB forecast page.

Pacific Biosciences Of California, Inc. Price Targets

Multiple analysts have issued price targets for $PACB recently. We have seen 3 analysts offer price targets for $PACB in the last 6 months, with a median target of $2.0.

Here are some recent targets:

Luke Sergott from Barclays set a target price of $1.0 on 04/14/2026
David Westenberg from Piper Sandler set a target price of $2.0 on 11/11/2025
Mason Carrico from Stephens & Co. set a target price of $2.0 on 11/10/2025